Status: Finalised First registered on: 27/03/2014
Last updated on: 27/08/2020
1. Study identification
EU PAS Register NumberEUPAS6161
Official titleA retrospective cohort study to investigate the initiation and persistence of dual antiplatelet treatment after acute coronary syndrome in a Finnish setting – THALIA
Study title acronymTHALIA
Study typeObservational study
Brief description of the studyMyocardial infarction affects about 5000 new patients in Finland every year. Approximately 20% of these patients die within one year after the event. Dual antiplatelet treatment (DAPT) with low dose acetylsalicylic acid and oral antiplatelet is recommended for patients with acute coronary syndromes. Guidelines recommend DAPT inhibition to be maintained up to over 12 months unless contraindications are present. New oral antiplatelets (OAP) have recently been introduced in the market in the Nordic countries. It is not known how the patient selection for different DAPT treatments and no-DAPT treatment happen. Neither are the persistence of OAP treatments, switch patterns between different OAP treatments, nor patient adherence to OAP treatments understood. The main objective of this study is to characterize and describe the patients treated with DAPT vs. non-DAPT treated patients, and the switch patterns and discontinuation rates of DAPT treatments. Approximately 200 000 patients discharged from Finnish hospitals following admission for unstable angina pectoris or myocardial infarction in 2009-2013 will be studied by using data from nationwide patient registers.
Was this study requested by a regulator?No
Is the study required by a Risk Management Plan (RMP)? Not applicable
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Centre to which the investigator belongsEPID Research
Department/Research group
Organisation/affiliationEPID Research Oy
Website/Homepagewww.epidresearch.com
Details of (Primary) lead investigator
Title Dr
Last name Prami
First name Tuire
Is this study being carried out with the collaboration of a research network?
No
Other centres where this study is being conducted
Not applicable (single centre)

Countries in which this study is being conducted
National study

Finland
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed23/01/2014
Start date of data collection04/08/201407/10/2014
Start date of data analysis01/05/201518/05/2015
Date of interim report, if expected
Date of final study report29/04/201615/10/2015
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companiesAstraZeneca Nordic Baltic100
Charities
Government body
Research councils
EU funding scheme
5. Contact details for enquiries
Scientific Enquiries
Title Dr
Last name Prami
First name Tuire
Address line 1EPID Research Oy
Address line 2Metsänneidonkuja 12 
Address line 3 
CityEspoo 
Postcode02130 
CountryFinland
Phone number (incl. country code)358505468459 
Alternative phone number 
Fax number (incl. country code) 
Email address tuire.prami@epidresearch.com
Public Enquiries
Title Dr 
Last name Prami 
First name Tuire 
Address line 1EPID Research Oy 
Address line 2Metsänneidonkuja 12 
Address line 3 
CityEspoo 
Postcode02130 
CountryFinland 
Phone number (incl. country code)358505468459 
Alternative phone number 
Fax number (incl. country code) 
Email address tuire.prami@epidresearch.com 
Top